Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer

Overview

Journal World J Oncol

Specialty Oncology

Date 2024 Jul 12

PMID 38993252

Authors

Sureyya Sarihan

Sema Gozcu Tunc

Zenciye Kiray Irem

Arda Kahraman

Gokhan Ocakoglu

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the study was to evaluate the efficacy of stereotactic body radiotherapy (SBRT) using the CyberKnife-M6 (CK-M6) with lung optimized treatment (LOT) module in patients with primary lung cancer and lung metastases.

Methods: Forty-two lesions from 35 patients were treated between 2019 and 2022. Four-dimensional computed tomography images were obtained when the patients were in a free breathing modality. Tracking modality was selected prospectively according to the visibility of the target. The median prescribed dose was 48 Gy in four fractions (fx) (28 - 55 Gy/1- 7 fx). The median age was 68 years (47 - 82 years), and 43% of cases were adenocarcinoma. The median lesion size was 15 mm (6 - 36 mm).

Results: Complete, partial and stable responses were obtained as 26%, 62%, and 9.5% at a median of 2 months (1 - 6 months), and 35.5%, 47.5% and 5% at the 12th month evaluation, respectively. Grade 3 and higher toxicity was not observed in any case. The mean and 2-year overall survival (OS) was 31.5 months and 54%, and the local recurrence-free survival (LRFS) was 29.6 months and 51%, respectively. In univariate analysis, target lesion type, complete response (CR), and higher esophagus maximum dose were favorable factors for OS and LRFS (P < 0.05). The CR at 12th month evaluation remained significant in multivariate analysis in terms of OS (hazard ratio = 8.602, 95% confidence interval: 1.05 - 70.01; P = 0.044).

Conclusions: A mean LRFS of 29.6 months and OS of 31.5 months were obtained in patients with primary and metastatic lung cancer. With a median treatment time of 25 min, motion-managed strategy with CK-M6-LOT-based SBRT is an effective, safe, and comfortable treatment method for lung cancer.

References

Yang Z, Chang Y, Liu H, Liu G, Li Q . Target margin design for real-time lung tumor tracking stereotactic body radiation therapy using CyberKnife Xsight Lung Tracking System. Sci Rep. 2017; 7(1):10826. PMC: 5589954. DOI: 10.1038/s41598-017-11128-w. View

Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersall P . The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2021; 16(7):1200-1210. DOI: 10.1016/j.jtho.2021.03.019. View

Khadige M, Salleron J, Marchesi V, Oldrini G, Peiffert D, Beckendorf V . Cyberknife stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months. J Thorac Dis. 2018; 10(8):4976-4984. PMC: 6129868. DOI: 10.21037/jtd.2018.07.26. View

Gizynska M, Rossi L, den Toom W, Milder M, de Vries K, Nuyttens J . Largely reduced OAR doses, and planning and delivery times for challenging robotic SBRT cases, obtained with a novel optimizer. J Appl Clin Med Phys. 2021; 22(3):35-47. PMC: 7984474. DOI: 10.1002/acm2.13172. View

Janvary Z, Jansen N, Baart V, Devillers M, Dechambre D, Lenaerts E . Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy. Radiol Oncol. 2017; 51(2):178-186. PMC: 5514658. DOI: 10.1515/raon-2017-0015. View

Bahig H, Campeau M, Vu T, Doucet R, Nadeau D, Fortin B . Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability for treatment of early non-small cell lung cancer: a single-center experience. Int J Radiat Oncol Biol Phys. 2013; 87(3):583-9. DOI: 10.1016/j.ijrobp.2013.06.2048. View

Sharma A, Duijm M, Oomen-de Hoop E, Aerts J, Verhoef C, Hoogeman M . Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2018; 57(8):1031-1037. DOI: 10.1080/0284186X.2018.1445285. View

Temming S, Kocher M, Stoelben E, Hagmeyer L, Chang D, Frank K . Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. Strahlenther Onkol. 2017; 194(2):91-97. DOI: 10.1007/s00066-017-1194-x. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

10.

Nakamura M, Nishimura H, Nakayama M, Mayahara H, Uezono H, Harada A . Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer. Br J Radiol. 2016; 89(1068):20160560. PMC: 5604921. DOI: 10.1259/bjr.20160560. View

11.

Huang B, Lu J, Lin P, Chen J, Li D, Chen C . Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy. Sci Rep. 2015; 5:18010. PMC: 4676016. DOI: 10.1038/srep18010. View

12.

Wang H, Zaorsky N, Meng M, Zeng X, Deng L, Song Y . Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget. 2016; 7(14):18135-45. PMC: 4951277. DOI: 10.18632/oncotarget.7636. View

13.

Francia C, Marvaso G, Piperno G, Gandini S, Ferrari A, Zerella M . Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma. 2020; 67(3):684-691. DOI: 10.4149/neo_2020_190717N645. View

14.

Tjong M, Malik N, Chen H, Gabriel Boldt R, Li G, Cheung P . Stereotactic ablative radiotherapy for malignant mediastinal and hilar lymphadenopathy: a systematic review. J Thorac Dis. 2020; 12(5):2280-2287. PMC: 7330368. DOI: 10.21037/jtd.2020.03.112. View

15.

Widder J, Hollander M, Ubbels J, Bolt R, Langendijk J . Optimizing dose prescription in stereotactic body radiotherapy for lung tumours using Monte Carlo dose calculation. Radiother Oncol. 2009; 94(1):42-6. DOI: 10.1016/j.radonc.2009.11.008. View

16.

Vogelius I, Bentzen S . A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012; 51(8):975-83. PMC: 3557496. DOI: 10.3109/0284186X.2012.718093. View

17.

Hayashi K, Suzuki O, Shiomi H, Ono H, Setoguchi A, Nakai M . Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors. BMC Cancer. 2023; 23(1):215. PMC: 9990197. DOI: 10.1186/s12885-023-10635-6. View

18.

Murphy M, Lin P, Ozhasoglu C . Intra-fraction dose delivery timing during stereotactic radiotherapy can influence the radiobiological effect. Med Phys. 2007; 34(2):481-4. DOI: 10.1118/1.2409750. View

19.

Xiao Y, Papiez L, Paulus R, Timmerman R, Straube W, Bosch W . Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 73(4):1235-42. PMC: 2911132. DOI: 10.1016/j.ijrobp.2008.11.019. View

20.

Zhang J, Yang F, Li B, Li H, Liu J, Huang W . Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2011; 81(4):e305-16. DOI: 10.1016/j.ijrobp.2011.04.034. View